Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Hexavalent DTaP-IPV-Hep B-PRP~T Vaccine in South Korean Infants
NCT02094833Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2014
- Primary completion
- Apr 2016
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of DTaP-IPV-Hep B-PRP-T vaccine in diphtheria, Tetanus, pertussis, poliomyelitis, hepatitis B (HBV), sponsored by Sanofi. Started Mar 2014; status: completed.
02
Drugs
DTaP-IPV-Hep B-PRP-T vaccine
03
Conditions
diphtheriaTetanuspertussispoliomyelitishepatitis B (HBV)
Beyond the preview
Go deeper on NCT02094833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02094833.